Bailitianheng (688506.SH): Injection use of BL-M14D1 (ADC) project for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notice.

On July 11th, Gelunhui reported that Baili Tianheng (688506.SH) recently received the "Drug Clinical Trial Approval Notice" officially issued by the National Medical Products Administration (NMPA). The clinical trial of the company's independently developed innovative biological drug BL-M14D1 (ADC) has been approved. BL-M14D1 is an ADC drug that shares the same "linker + toxin" platform as BL-B01D1, both of which are derived from the same small molecule technology platform. Its indication is late-stage solid tumors.

Gelonghui FinanceJul 11 06:40 ET

Sichuan Biokin Pharmaceutical Submits Hong Kong IPO Application

Sichuan Biokin Pharmaceutical (SHA:688506) submitted its application to list its H shares on the Hong Kong Stock Exchange, according to documents submitted to the bourse Wednesday.The

MT NewswiresJul 11 04:16 ET

Bailey Tianheng (688506.SH) has submitted an application for the listing of H shares to the Stock Exchange of Hong Kong.

Bailitianheng (688506.SH) announced that the company is applying for a public offering of overseas listed stocks (H shares) and ...

Zhitong FinanceJul 10 18:21 ET

Biokin Pharmaceutical Enrolls First Patient in Breast Cancer Drug Trial

Sichuan Biokin Pharmaceutical (SHA:688506) completed the enrollment of the first patient in a phase 3 clinical trial of its breast cancer treatment candidate, according to a Thursday filing with the S

MT NewswiresJul 4 00:20 ET

Bailitanheng (688506.SH): The first subject was enrolled in the phase III clinical trial of BL-B01D1 for locally advanced or metastatic triple-negative breast cancer.

On July 3rd, Gelunhui reported that Bailitianheng (688506.SH) announced that the Phase III clinical trial of BL-B01D1 (EGFR×HER3-ADC) injection, an innovative biological drug independently developed and used alone for unresectable locally advanced or metastatic triple-negative breast cancer that has failed previously treated with taxanes, has completed the first subject enrollment. So far, BL-B01D1 monotherapy has been registered for Phase III clinical trials in domestic terminal nasopharyngeal carcinoma, line 2 esophageal squamous cell carcinoma, HR+HER2- breast cancer, EGFR mutation type non-small cell lung cancer, and EGFR wild-type non-small cell lung cancer.

Gelonghui FinanceJul 3 07:36 ET

Express News | Biokin Pharma Says It Plans to Issue Shares and List in Hong Kong

ReutersJun 21 08:21 ET